Research programme: CD26 antigen antagonists - Morphochem/Probiodrug

Drug Profile

Research programme: CD26 antigen antagonists - Morphochem/Probiodrug

Alternative Names: PD IV inhibitors - Morphochem/Probiodrug; Serine protease dipeptidyl peptidase IV inhibitors - Morphochem/Probiodrug

Latest Information Update: 22 Jul 2010

Price : $50

At a glance

  • Originator Morphochem AG; Probiodrug
  • Class Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anxiety disorders; Major depressive disorder

Most Recent Events

  • 01 Dec 2005 Morphochem AG has been acquired by Biovertis AG
  • 18 Nov 2004 Preclinical trials in Depression in Germany (PO)
  • 18 Nov 2004 Preclinical trials in Anxiety disorders in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top